Tag: Ovarian Cancer

Doublet maintenance therapy does not outperform monotherapy in ovarian cancer

Presented By
Prof. Bradley Monk, University of Arizona, AZ, USA
Trial
Phase 3, ATHENA-COMBO
Conference
ESMO 2024
Type
Peer-reviewed article

4 November 2024 11:25

No OS benefit of niraparib maintenance in high-risk ovarian cancer

Presented By
Dr Antonio González-Martin, Clínica Universidad de Navarra, Spain
Trial
Phase 3, PRIMA
Conference
ESMO 2024
Type
Peer-reviewed article

4 November 2024 11:15

Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer

Presented By
Dr Katherine Fuh, University of California San Francisco, CA, USA
Trial
Phase 3, AXLerate-OC
Conference
ASCO 2024
Type
Peer-reviewed article

18 July 2024 13:38

No lymphadenectomy for advanced ovarian cancer without suspicious nodes

Presented By
Prof. Jean-Marc Classe, Nantes Université, France
Trial
Phase 3, CARACO
Conference
ASCO 2024
Type
Peer-reviewed article

18 July 2024 13:34

Join the conversation on Rare Disease Awareness Day

Expert
Prof. Rachel Giles

26 February 2024 11:42

Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer

Presented By
Prof. Antonio Gonzalez Martin, Cancer Centre Clinica Universidad de Navarre, Spain
Trial
Phase 3, ANITA
Conference
ESMO 2023
Type
Peer-reviewed article

19 December 2023 12:43

Top 10 medical breakthroughs in 2023

Expert
Dr Alex McDonald (Board member, Physician’s Weekly) and Dr Rachel Giles (Medical Science Officer, Medicom Medical Publishers)

18 December 2023 15:29

Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer

Presented By
Dr Philipp Harter, Kliniken Essen-Mitte, Germany
Trial
Phase 3, DUO-O
Conference
ASCO 2023
Type
Peer-reviewed article

1 August 2023 12:44

OS benefit for advanced ovarian cancer patients treated with maintenance olaparib

Presented By
Prof. Isabelle Ray-Coquard, Centre Léon Bérard, France
Trial
Phase 3, PAOLA-1/ENGOT-ov25
Conference
ESMO 2022
Type
Peer-reviewed article

17 November 2022 00:57

Primary results of rucaparib in ovarian cancer 

Presented By
Prof. Bradley Monk, University of Arizona, AZ, USA
Trial
Phase 3, ATHENA-MONO
Conference
ASCO 2022
Type
Peer-reviewed article

5 August 2022 15:28

Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer 

Presented By
Dr Domenica Lorusso, San Raffaele Scientific Institute, Italy
Trial
Phase 3, MIT023
Conference
ASCO 2022
Type
Peer-reviewed article

5 August 2022 15:25

Encouraging results of relacorilant in ovarian cancer

Presented By
Prof. Nicoletta Colombo, University of Milan, Italy
Conference
ASCO 2022
Type
Peer-reviewed article

5 August 2022 15:23

PARP inhibitor rechallenge improves PFS in ovarian cancer

Presented By
Dr Eric Pujade-Lauraine, Université Paris Descartes, France
Trial
Phase 3, OReO/ENGOT Ov-38
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:24

HRR mutational status is prognostic and predictive biomarker olaparib activity

Presented By
Dr Joyce Liu, Dana-Farber Cancer Institute, MA, USA
Trial
Phase 3, NRG-GY004
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:20

Novel drug combination for recurrent ovarian cancer

Presented By
Prof. David O’Malley, Ohio State University, OH, USA
Trial
Phase 1/2, FORWARD II
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 22:43

The EFFORT needed to overcome PARP resistance in ovarian cancer

Presented By
Dr. Shannon Neville Westin, University of Texas, MD Anderson Center
Trial
Phase 2, EFFORT
Journal
Physician's Weekly
Conference
ASCO 2021

6 August 2021 12:40

Treatment of newly diagnosed ovarian cancer

Conference
ESMO 2020
Type
Peer-reviewed article

25 November 2020 14:39

Treatment of recurrent ovarian cancer

Conference
ESMO 2020
Type
Peer-reviewed article

25 November 2020 14:35

Ovarian cancer patients benefit from combined maintenance therapy

Presented By
Prof. Isabelle Ray-Coquard, Université Claude Bernard, Lyon, France
Trial
Phase 3, PAOLA-1/ENGOT-ov25
Conference
ESMO 2019
Type
Peer-reviewed article

26 November 2019 23:25

Combination of PARP inhibition plus chemotherapy in ovarian cancer

Presented By
Robert Coleman, University of Texas, MD Anderson Cancer Center, Houston, USA
Trial
Phase 3, VELIA
Conference
ESMO 2019
Type
Peer-reviewed article

26 November 2019 22:26

PFS benefit with niraparib as first-line maintenance in ovarian cancer

Principal Investigator
Prof. Antonio González Martín, Clinica Universidad de Navarra, Spain
Trial
Phase 3, PRIMA/ENGOT-OV26/GOG-3012
Conference
ESMO 2019
Type
Peer-reviewed article

26 November 2019 14:26
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com